keyword
MENU ▼
Read by QxMD icon Read
search

rivaroxaban in hemodialysis

keyword
https://www.readbyqxmd.com/read/27548702/rivaroxaban-in-chronic-hemodialysis-patients-clarification-of-an-editorial-error
#1
Clapton Dias, Kenneth Todd Moore, Joe Murphy, Jay Ariyawansa, William Smith, Roger M Mills, Matthew R Weir
No abstract text is available yet for this article.
2016: American Journal of Nephrology
https://www.readbyqxmd.com/read/27100995/rivaroxaban-in-chronic-hemodialysis-patients
#2
Heather Muster, Harry Alcorn
No abstract text is available yet for this article.
2016: American Journal of Nephrology
https://www.readbyqxmd.com/read/27100875/pharmacokinetics-pharmacodynamics-and-safety-of-single-dose-rivaroxaban-in-chronic-hemodialysis
#3
Clapton Dias, Kenneth Todd Moore, Joe Murphy, Jay Ariyawansa, William Smith, Roger M Mills, Matthew R Weir
BACKGROUND: This study aimed to characterize the single-dose pharmacokinetic (PK) and pharmacodynamic (PD) profile of rivaroxaban 15 mg administered before and after dialysis in subjects with end-stage renal disease (ESRD), and to compare this profile in subjects with ESRD to that in healthy control subjects (creatinine clearance ≥80 ml/min). METHODS: This was an open-label, single-dose, single-center, parallel-group study of rivaroxaban in ESRD subjects who had been clinically stable on maintenance hemodialysis for ≥3 months...
2016: American Journal of Nephrology
https://www.readbyqxmd.com/read/27082776/specific-antidotes-against-direct-oral-anticoagulants-a-comprehensive-review-of-clinical-trials-data
#4
REVIEW
Ramyashree Tummala, Ana Kavtaradze, Anjan Gupta, Raktim Kumar Ghosh
The Vitamin K antagonist warfarin was the only oral anticoagulant available for decades for the treatment of thrombosis and prevention of thromboembolism until Direct Oral Anticoagulants (DOACs); a group of new oral anticoagulants got approved in the last few years. Direct thrombin inhibitor: dabigatran and factor Xa inhibitors: apixaban, rivaroxaban, and edoxaban directly inhibit the coagulation cascade. DOACs have many advantages over warfarin. However, the biggest drawback of DOACs has been the lack of specific antidotes to reverse the anticoagulant effect in emergency situations...
July 1, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/26814780/the-epidemic-of-pre-injury-oral-antiplatelet-and-anticoagulant-use
#5
A E Berndtson, R Coimbra
BACKGROUND: As the population ages, an increasing number of trauma patients are taking antiplatelet and anticoagulant medications (ACAP) prior to their injuries. These medications increase their risk of hemorrhagic complications, particularly intracerebral hemorrhage. Clopidogrel and warfarin are common and their mechanisms well understood, but optimal reversal methods continue to evolve. The novel direct thrombin and factor Xa inhibitors are less well described and do not have existing antidotes...
December 2014: European Journal of Trauma and Emergency Surgery: Official Publication of the European Trauma Society
https://www.readbyqxmd.com/read/26588018/new-insights-into-nonvitamin-k-antagonist-oral-anticoagulants-reversal-of-intracerebral-hemorrhage
#6
REVIEW
Masahiro Yasaka
The nonvitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban are associated with an equal or lower incidence of stroke and systemic embolism and a much lower incidence of intracranial hemorrhage and hemorrhagic stroke than warfarin is, without the need for routine laboratory monitoring. However, reversal strategies are not currently established in the case of NOAC-related hemorrhagic stroke. In emergency situations, well-defined management for NOAC-related hemorrhagic stroke may improve clinical outcomes...
2015: Frontiers of Neurology and Neuroscience
https://www.readbyqxmd.com/read/26508464/gastrointestinal-bleeding-in-patients-receiving-oral-anticoagulation-current-treatment-and-pharmacological-perspectives
#7
REVIEW
Alessandro Di Minno, Gaia Spadarella, Emanuela Spadarella, Elena Tremoli, Giovanni Di Minno
Gastrointestinal bleeding (GIB) is a potentially fatal and avoidable medical condition that poses a burden on global health care costs. The rate of major GIB related to the use of some direct acting oral anticoagulant drugs (DOACs), is higher than that detected in warfarin users. Current strategies in the treatment of GIBs in patients receiving warfarin or DOACs (vitamin K, activated charcoal; hemodialysis; recombinant factor VIIa; [activated] prothrombin complex concentrates) including indications for the treatment of bleeding based on different degrees of severity of the episodes, is reported in this article...
December 2015: Thrombosis Research
https://www.readbyqxmd.com/read/26171862/characteristics-of-symptomatic-intracranial-hemorrhage-in-patients-receiving-non-vitamin-k-antagonist-oral-anticoagulant-therapy
#8
Hisanao Akiyama, Kenji Uchino, Yasuhiro Hasegawa
OBJECTIVES: The first non-vitamin K antagonist oral anticoagulant (NOAC) introduced to the market in Japan was dabigatran in March 2011, and three more NOACs, rivaroxaban, apixaban, and edoxaban, have since become available. Randomized controlled trials of NOACs have revealed that intracranial hemorrhage (ICH) occurs less frequently with NOACs compared with warfarin. However, the absolute incidence of ICH associated with NOACs has increased with greater use of these anticoagulants, and we wanted to explore the incidence, clinical characteristics, and treatment course of patients with NOACs-associated ICH...
2015: PloS One
https://www.readbyqxmd.com/read/26088576/antidotes-for-novel-oral-anticoagulants-current-status-and-future-potential
#9
REVIEW
Mark Crowther, Mark A Crowther
The direct thrombin inhibitor dabigatran and the anti-Xa agents rivaroxaban, edoxaban, and apixaban are a new generation of oral anticoagulants. Their advantage over the vitamin K antagonists is the lack of the need for monitoring and dose adjustment. Their main disadvantage is currently the absence of a specific reversal agent. Dabigatran's, unlike the anti-Xa agents, absorption can be reduced by activated charcoal if administered shortly after ingestion and it can be removed from the blood with hemodialysis...
August 2015: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/25804678/dose-finding-study-of-rivaroxaban-in-hemodialysis-patients
#10
MULTICENTER STUDY
An S De Vriese, Rogier Caluwé, Els Bailleul, Dirk De Bacquer, Daniëlle Borrey, Bruno Van Vlem, Stefaan J Vandecasteele, Jan Emmerechts
BACKGROUND: Use of vitamin K antagonists for the prevention of stroke and systemic embolism in dialysis patients with nonvalvular atrial fibrillation is controversial. However, no good alternatives presently are available. The anti-factor Xa antagonist rivaroxaban is contraindicated for lack of pharmacokinetic, pharmacodynamic, and clinical data. This study aims to characterize the pharmacokinetics/pharmacodynamics of rivaroxaban in maintenance hemodialysis patients. STUDY DESIGN: Pharmacokinetic and pharmacodynamic study...
July 2015: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/25636144/comparison-of-novel-oral-anticoagulants-versus-vitamin-k-antagonists-in-patients-with-chronic-kidney-disease
#11
REVIEW
Ziv Harel, Manish M Sood, Jeffrey Perl
PURPOSE OF REVIEW: Novel oral anticoagulants (NOACs) including apixaban, dabigatran and rivaroxaban have been approved by international regulatory agencies to prevent venous thromboembolism as well as treat atrial fibrillation and venous thromboembolism in individuals with chronic kidney disease (CKD). However, alterations in their metabolism in the setting of CKD may impact their efficacy and lead to an increased risk of bleeding. This review summarizes the current literature on the efficacy and safety of these agents in individuals with moderate CKD...
March 2015: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/25595139/dabigatran-and-rivaroxaban-use-in-atrial-fibrillation-patients-on-hemodialysis
#12
Kevin E Chan, Elazer R Edelman, Julia B Wenger, Ravi I Thadhani, Franklin W Maddux
BACKGROUND: Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the kidneys. Their use in dialysis patients is discouraged because these drugs can bioaccumulate to precipitate inadvertent bleeding. We wanted to determine whether prescription of dabigatran or rivaroxaban was occurring in the dialysis population and whether these practices were safe. METHODS AND RESULTS: Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation...
March 17, 2015: Circulation
https://www.readbyqxmd.com/read/25502131/managing-bleeding-and-emergency-reversal-of-newer-oral-anticoagulants-a-review-for-primary-care-providers
#13
W Frank Peacock
The therapeutic landscape for anticoagulation management is undergoing a shift from the use of traditional anticlotting agents such as heparins and warfarin as the only options to the growing adoption of newer target-specific oral anticoagulants (TSOACs) with novel mechanisms of action. Dabigatran, the first TSOAC approved for use in the United States, is a direct competitive inhibitor of thrombin. It has predictable kinetics, with an elimination half-life of 12 to 17 hours in healthy volunteers. Apixaban and rivaroxaban are selective inhibitors of factor Xa, and also display first-order kinetics...
October 2014: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/25485923/strategies-for-urgent-reversal-of-target-specific-oral-anticoagulants
#14
REVIEW
Estella M Davis, Erin M Uhlmeyer, David P Schmidt, Greg L Schardt
The direct thrombin inhibitor dabigatran and factor Xa inhibitors rivaroxaban and apixaban are US Food and Drug Administration (FDA)-approved target-specific oral anticoagulants (TSOACs) that have emerged onto the market for use in some indications similar to those for warfarin; in addition, edoxaban is seeking FDA approval. Similar indications include reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation for all 3 agents, for the prevention of deep vein thrombosis that may lead to pulmonary embolism in patients undergoing hip or knee surgery for rivaroxaban and apixaban, and for the treatment and prevention of deep vein thrombosis and pulmonary embolism...
December 2014: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/24979070/-new-direct-oral-anticoagulants-in-the-perioperative-setting
#15
REVIEW
Georg Breuer, Dominik R Weiss, Juergen Ringwald
PURPOSE OF REVIEW: Out of the anesthetist's perspective, some uncertainties remain with the perioperative management of the so-called NOACs. This review emphasizes on the question of bleeding and thromboembolic risk as well as the management of bleedings and the discontinuing intervals in the context of regional anesthesia. RECENT FINDINGS: Managing patients with NOAC therapy, an interdisciplinary approach and consent with surgeons and specialist in hemostaseology has to be found...
August 2014: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/24711240/-perioperative-management-and-therapy-of-bleeding-complications
#16
Christian von Heymann, Lutz Kaufner, Mareike Körber
The new oral anticoagulants directly inhibit either thrombin (Dabigatran, Pradaxa®,) or activated Factor X (rivaroxaban, Xarelto®, and apixaban, Eliquis®) and have been approved for thromboprophylaxis after hip and knee replacement surgery and stroke prevention in non-valvular atrial fibrillation. Moreover, rivaroxaban has been approved for the treatment of deep venous thrombosis, prevention of pulmonary embolism and anticoagulation after acute myocardial infarction. The direct FXa-inhibitor edoxaban (Lixiana®) expects approval for the prevention of stroke in atrial fibrillation in Germany in 2014...
March 2014: Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie: AINS
https://www.readbyqxmd.com/read/23790601/stroke-prevention-in-atrial-fibrillation-patients-with-chronic-kidney-disease
#17
REVIEW
Robert G Hart, John W Eikelboom, K Scott Brimble, M Sean McMurtry, Alistair J Ingram
Chronic kidney disease (CKD) is prevalent in elderly patients with atrial fibrillation and is an independent risk factor for stroke. Warfarin anticoagulation is efficacious for stroke prevention in atrial fibrillation patients with moderate CKD (stage III, estimated glomerular filtration rate 30-59 mL/min), but recent observational studies have challenged its value for patients with end-stage renal disease requiring dialysis. The novel oral anticoagulants (i.e., dabigatran, apixaban, rivaroxaban) all undergo renal metabolism to varying degrees, and hence dosing, efficacy, and safety require special consideration in CKD patients...
July 2013: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/23640529/developing-a-management-plan-for-oral-anticoagulant-reversal
#18
William E Dager
PURPOSE: To describe a process for prompt evaluation and management- including reversal of the effects of warfarin and target-specific oral anticoagulants-of patients with or at high risk for bleeding during oral anticoagulant therapy or when such therapy is interrupted for an urgent invasive procedure or surgery. SUMMARY: The use of pharmacologic interventions for anticoagulant reversal may depend on the measured level of anticoagulation, time since the last anticoagulant dose, target level of coagulation, reliability of laboratory tests of coagulation, severity of or risk for bleeding, the agents' mechanism of action and pharmacokinetics, and pharmacodynamics of the reversal agent...
May 15, 2013: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/23494907/treatment-of-bleeding-complications-when-using-oral-anticoagulants-for-prevention-of-strokes
#19
Frank Akwaa, Alex C Spyropoulos
Major bleeding in patients taking oral anticoagulants for stroke prevention can progress to catastrophic bleeding if it is not controlled. This is especially of concern if the bleeding is related to the use of a novel oral anticoagulant (NOAC) such as dabigatran or rivaroxaban, given the dearth of literature addressing the reversal of their anticoagulant effects. The goal of treatment is to prevent progression to catastrophic hemorrhage or exsanguination, and decrease bleeding-related morbidity and mortality...
June 2013: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/23416382/managing-new-oral-anticoagulants-in-the-perioperative-and-intensive-care-unit-setting
#20
REVIEW
Jerrold H Levy, David Faraoni, Jenna L Spring, James D Douketis, Charles M Samama
Managing patients in the perioperative setting receiving novel oral anticoagulation agents for thromboprophylaxis or stroke prevention with atrial fibrillation is an important consideration for clinicians. The novel oral anticoagulation agents include direct Factor Xa inhibitors rivaroxaban and apixaban, and the direct thrombin inhibitor dabigatran. In elective surgery, discontinuing their use is important, but renal function must also be considered because elimination is highly dependent on renal elimination...
June 2013: Anesthesiology
keyword
keyword
120440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"